InsiderTrades

Form 4 for ELVN Enliven Therapeutics, Inc.

Accepted 2025-03-26 00:00:00 ET · period of report 2025-03-24 · accession 0001415889-25-009066 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-03-26 2025-03-24 ELVN Hohl Benjamin CFO M - OptEx $2.48 +1,000 24.0K +4% +$2,480
D 2025-03-26 2025-03-24 ELVN Hohl Benjamin CFO S - Sale+OE $22.50 -1,000 23.0K -4% -$22.5K
D 2025-03-26 2025-03-24 ELVN Hohl Benjamin CFO M - OptEx $0.00 -1,000 131.8K -0.8% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-03-24 M A 1,000 $2.48 24,000 D — —
2 Common Common Stock 2025-03-24 S D 1,000 $22.50 23,000 D — — (F2) This transaction was executed in multiple trades at prices ranging from $22.50 to $22.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3 Derivative Stock Option (right to buy) 2025-03-24 M D 1,000 $0.00 131,806 D $2.48 · — to 2031-08-02 1,000 Common Stock (F3) The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.